Regeneron Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

 Global Phase 1/2 CHORD trial investigating otoferlin gene therapy (DB-OTO) represents Regeneron’s first auditory program and is currently enrolling patients

DB-OTO is part of a growing pipeline of genetic medicines for hearing loss and other therapeutic areas that are being advanced by the company

https://www.globenewswire.com/news-release/2023/10/26/2767955/0/en/Regeneron-Shares-Preliminary-Results-Showing-Gene-Therapy-Improves-Auditory-Responses-in-Child-with-Profound-Genetic-Hearing-Loss.html